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A new generation of diagnostic tests is being developed for use at the point of care that 
could save lives and reduce the spread of infectious diseases through early detection and 
treatment. It is important that patients in developing countries have access to these products 
at affordable prices and without delay. Regulation of medical products is intended to ensure 
safety and quality whilst balancing the need for timely access to beneficial new products. 
Current regulatory oversight of diagnostic tests in developing countries is highly variable 
and weak regulation allows poor-quality tests to enter the market. However, inefficient or 
overzealous regulation results in unnecessary delays, increases costs and acts as a barrier to 
innovation and market entry. Setting international standards and streamlining the regulatory 
process could reduce these barriers. Four priority activities have been identified where 
convergence of standards and protocols or joint review of data would be advantageous: (1) 
adoption of a common registration file for pre-market approval; (2) convergence of quality 
standards for manufacturing site inspections; (3) use of common evaluation protocols, as 
well as joint review of data, to reduce unnecessary duplication of lengthy and costly clinical 
performance studies; and (4) use of networks of laboratories for post-market surveillance in 
order to monitor ongoing quality of diagnostic devices. The adoption and implementation of 
such measures in developing countries could accelerate access to new diagnostic tests that are 
safe and affordable.  
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Introduction 
Diagnostic tests make a major contribution to global health. They are needed in order to guide 
treatment decisions and ensure the appropriate use of medicines. They are also vital for screening 
for infections, such as HIV infection or syphilis, in asymptomatic individuals.1 Such tests are often 
lifesaving, where delay or lack of access can result in deterioration of the patient’s health and 
lead to further complications. Diagnostics are particularly important for the control of infectious 
diseases, where early detection allows intervention in order to prevent onward transmission.2 
They may also be used to monitor the outcome of treatment. Most diagnostic interventions utilise 
in vitro diagnostic medical devices (IVDs) which test specimens obtained from a patient, such as 
blood or urine. IVDs include a wide range of technologies, from rapid dip-stick strips for use at 
the point of care (POC) to sophisticated instrumentation for use in referral laboratories. Access to 
diagnostic tests in developing countries is often limited by their availability, as patients frequently 
do not live within easy travelling distance of a well-equipped and functional laboratory.2,3 A new 
generation of diagnostic tests is being developed for use at the point of care that will not need 
a laboratory.4,5 Prompt access to the new tests should be encouraged; if they are made available 
in developing countries at affordable prices, such tests could increase access to appropriate 
healthcare, thereby saving lives and reducing the spread of infectious diseases.4,5,6 
Regulating diagnostic devices
Regulation of medical products is intended to ensure safety and quality whilst ensuring that the 
public has timely access to beneficial new products. National Regulatory Authorities (NRAs) are 
usually mandated by law and, for a regulatory system to be effective, it should be enforceable 
in both the public and private healthcare sector. Following impartial review, new tests that are 
considered substandard or unsafe are refused entry to the market, whereas satisfactory products 
are approved and registered. For regulatory purposes, IVDs are classified as medical devices. In 
this context, ‘medical device’ means any instrument, apparatus, implement, machine, appliance, 
implant, reagent for in vitro use, software, material, or any other similar or related article intended 
by the manufacturer to be used alone or in combination, for human beings for one or more of the 
specific medical purpose(s): diagnosis, prevention, monitoring, treatment or alleviation of disease; 
diagnosis, monitoring, treatment, alleviation of or compensation for an injury; investigation, 
replacement, modification or support of the anatomy or of a physiological process; support or 
sustenance of life; control of conception; disinfection of medical devices; provision of information 
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by means of in vitro examination of specimens derived from 
the human body.7 An IVD is defined as:
medical device, whether used alone or in combination, intended 
by the manufacturer for the in vitro examination of specimens 
derived from the human body solely or principally to provide 
information for diagnostic, monitoring or compatibility 
purposes.7
Most countries have a legal framework and a nominated 
body to regulate medicines, but regulation of medical 
devices in developing countries is less common.8 The 
demands on regulatory authorities for IVDs differ from 
that of other medical products in that there are a very large 
number of IVDs and, compared with drugs or vaccines, their 
market life is often short given the rapid pace of technology 
development.9 Current regulatory oversight of IVDs is 
variable8 and, in countries where there is no regulation, 
substandard and counterfeit tests may be sold openly.10 In 
countries that do regulate, approval for IVDs is often costly, 
lengthy and, on occasion, lacking in transparency, thus 
regulation of diagnostics is currently seen as a barrier to 
innovation and access.9,11,12 In 2001, the Pan American Health 
Organisation (PAHO), the Regional Office for the Americas 
of the World Health Organization (WHO) and the United 
States Food and Drug Administration (USFDA) published 
a model regulatory programme for medical devices, with 
a set of guiding principles.13 These principles include the 
statement that:
regulatory system should ensure that valuable new technologies 
are made available to the clinical community and to patients and 
consumers expeditiously while preventing unsafe or ineffective 
devices from reaching the market.13  
They also state that regulatory decisions must be based on 
strong and clear science, free of external influences and, in 
addition, that countries instituting regulatory programmes 
should be cognisant of ongoing international efforts to 
harmonise activities. 
Regulatory control of IVD has three components: 
•	 Pre-market evaluation: to assess safety, performance, 
benefits and risks prior to approval to market the device.
•	 Marketing controls: to stipulate conditions under which 
devices can be offered for sale; identify who may use 
the device and under what conditions; and to avoid 
inappropriate marketing or misleading claims regarding 
test effectiveness.
•	 Post-marketing controls: to maintain vigilance and 
continued safety and quality of approved products that 
entails a method for information-sharing amongst users 
within the country and across national health authorities. 
There should be a means by which corrections can be 
made as well as a mechanism for removing substandard 
products that pose a risk to public health.
Risk classification of in vitro diagnostic medical 
devices 
The degree of regulatory control for a medical device should 
be proportionate to the risk posed by the product. Unlike 
medicines or vaccines, IVDs are not ingested by the patient, 
greatly reducing the potential for harm. Thus  the stringency 
of regulatory oversight required is related to the harm that a 
false positive or false negative test result may cause to either 
individual or public health. Reagents used in diagnostics 
tests, such as microbiological stains or culture media, by 
themselves pose little risk to human or public health and 
are classed as low risk. High risk tests include those used 
to screen for infections such as HIV, where a false negative 
test result could lead to the individual not being given 
life-saving drugs and continuing to transmit the infection 
within the community. Should the test be used to screen 
blood products, then recipients of that donation would be 
at risk of acquiring a life-threatening disease. Such tests 
require more stringent control, including evidence of their 
performance as obtained through clinical studies. To guide 
the regulatory process, products are grouped or classified 
according to their risk of causing harm. In 2006, the Global 
Harmonization Task Force (GHTF), a voluntary partnership 
of stringent regulatory authorities and diagnostic companies, 
published recommendations regarding classification of 
medical devices. They suggested that each medical device be 
assigned to one of four classes based upon its intended use 
(Table 1).14 Classification provides a mechanism by which 
the cost and delay of registration are moderated according 
to the potential of a product to cause harm. Manufacturers 
are required to provide less-substantial submission dossiers 
for products in risk group Class A; whereas Class D products 
require stringent conformity assessment, including evidence 
of performance in a clinical setting that is representative of 
the intended use. For devices to be used at the POC, studies 
should be conducted in the settings of intended use (clinic 
or outreach settings) with testing performed by local health 
providers. Such studies are costly and, for some diseases, 
may require years to plan and execute. The classification 
system requires a shorter and less-costly route to pre-market 
approval for low-risk products.
Harmonising regulation of diagnostic devices
Whilst regulation of medical products is required in order 
to ensure their safety, it is essential that regulatory review 
processes do not obstruct or unnecessarily delay access to 
beneficial new products. It is recognised that the current 
lack of standardisation across national regulatory authorities 
and the lack of clarity surrounding the regulatory pathways 
presents an unnecessary burden on manufacturers and acts 
as a deterrent to marketing in countries where the financial 
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TABLE 1: Classification of medical devices with examples of diagnostic products.
Class Risk Level Examples
A Low individual risk and low public health risk Stains, culture reagents
B Moderate individual risk and/or low public health risk Home-use pregnancy tests, urine test strips  
C High individual risk and/or moderate public health risk Rapid tests for rubella, malaria
D High individual risk and high public health risk Blood screening tests for HIV, Hepatitis B and C, or Human T-cell lymphotropic virus
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returns may be modest.9 With the exception of the countries 
of the European Union, where a harmonised system has been 
adopted, countries each have their own set of requirements. 
In some countries, transparency is lacking, with little 
information available about the regulatory process or the 
fees charged. Several transnational initiatives are striving 
toward improved harmonisation of regulation of medical 
devices, including IVDs (Table 2). Harmonisation requires 
the use of standardised terminology and definitions which 
are employed to classify the products under regulation. 
Guidance on this topic was issued by the GHTF, which 
transitioned to the International Medical Device Regulators 
Forum (IMDRF) in 2012.  
For IVDs used in developing countries there are opportunities 
to streamline and harmonise activities where convergence of 
protocols and mutual recognition of other regulatory bodies 
could improve their safety and quality, accelerating access 
to new tests while simultaneously minimising the costs 
incurred. Setting international standards and streamlining 
the regulatory process could reduce the regulatory burden 
and lower costs of new products. Four priority areas 
for harmonisation have been recognised: (1) adoption 
of common registration requirements and submission 
dossiers for pre-market approval; (2) convergence of quality 
standards and mutual, or third party, recognition of audit 
activities; (3) rationalisation of clinical performance studies 
in order to avoid unnecessary duplication; and (4) building 
of transnational networks for post-market surveillance. Each 
of the aforementioned areas of harmonisation is discussed in 
the following sections. The status quo and need for change 
are described, along with recommendations made for the 
way forward. The impact of the proposed harmonisation 
activities are summarised in Table 3.
A Common Submission Dossier 
Companies seeking approval to market an IVD are required 
to supply a dossier to the appropriate NRA describing the 
device and documenting evidence relating to the quality 
of manufacture, as well as the safety and stability of the 
components. In addition, those devices considered to be at 
risk of causing harm to either individual or public health also 
require evidence regarding the clinical performance of the 
device. The adoption of a standardised submission dossier 
template would promote efficiency within the regulatory 
review process and facilitate standardised training on good 
review practice using a common set of teaching materials. 
NRAs would retain independent review of the data, 
along with any decisions for approval based on national 
requirements as they pertain to their local population needs. 
The need for a common submission dossier was one of the 
top priorities recognised by the GHTF and was an activity 
already adopted by the Asian Harmonisation Working Party 
(AHWP).15
Status quo
With the exception of the European Union, submission 
dossiers are unique to the country, with each NRA utilising 
its own indicators, nomenclature and format in its own 
language.9,16 Preparation of a submission dossier for 
regulatory approval is a substantial undertaking and the 
necessity of preparing individual dossiers and reformulating 
data for each NRA is an unnecessary burden on diagnostic 
companies, causing overall increase to the cost of marketing 
a new product. In countries with weak economies, small 
populations or low prevalence of the condition or disease 
to be tested, the anticipated market may be insufficient to 
warrant the cost of registering the product. The problem 
is particularly acute for small companies with limited 
regulatory expertise or capacity. Large companies are also 
not exempt from the burden that a submission dossier 
carries, as it represents a significant commitment of resources 
and time. A standardised template for submission dossiers 
would decrease the time and effort required of companies, 
improve the efficiency of regulatory reviews and reduce the 
TABLE 2: Organisations promoting regulatory harmonisation of medical devices or in vitro diagnostics.
Name Regional focus Membership 
Global Harmonisation Task Force (GHTF)* Global NRAs and manufacturers. Founding Members: Australia, Canada, the European Union, 
Japan and the United States
International Medical Device Regulators Forum (IMDRF) Global NRAs: Australia, Canada, the European Union, Japan and the United States. China and 
the Russian Federation to be confirmed. WHO has observer status
Asian Harmonisation Working Party (AHWP) www.ahwp.info Asia 23 member economies: regulators and companies  
Latin America IVD Association (ALADDIV) Latin America Forum for regulators, researchers, laboratory experts and representatives from 
ministries of health
Pan-African Harmonisation Working Party (PAHWP) www.pahwp.org Africa African regulators, laboratory experts, manufacturers and international organisations 
*, Disbanded 2012 and reformulated as IMDRF; NRA, national regulating authority; WHO, World Health Organization.
TABLE 3: Expected impact of harmonisation activities.
Item Status quo Proposed harmonisation model Impact
Dossier for registration Forms unique to each country Common template submission Standard dossier conforming to international 
standards whilst saving companies time, 
effort and expense
Quality systems audit ISO 13485 Unique visits by NRAs; delay in 
approval due to long queues and high costs to 
companies
Adoption of common standard
Mutual recognition of audits
Recognition of third party audits by an 
‘accredited’ body
Shortened times to approval and reduced 
costs
Faster access to tests for patients
Clinical studies Large number of studies conducted for each 
product
Common protocols
Network of competent sites
Joint review of data but final approval country 
specific
Approval in more countries with fewer trials
Clear path for approval; reduced costs and 
time to approval yielding improved access 
by patients
Post-marketing surveillance Limited capacity for identifying low quality 
products and product failures
Network of evaluation sites for post-marketing 
surveillance
Ensured quality of tests post-approval
Opinion Papers
doi:10.4102/ajlm.v3i1.123http://www.ajlmonline.org
Page 4 of 7
cost of goods for diagnostic companies, resulting in a more 
affordable product and overall reduced time to market.   
Action going forward
Following principles established by the GHTF, the AHWP 
has developed a Common Submission Dossier Template 
(CSDT) for premarket submission of IVDs. The dossier 
incorporates: (1) marketing history and, where appropriate, 
a risk/benefit assessment, any prior approvals and current 
regulatory status, as well as documentation to demonstrate 
conformity to the essential principles of the GHTF; (2) a 
product description which includes intended use and any 
warnings or precautions; (3) a summary of design verification 
and validation documents – these may include sensitivity, 
specificity, precision, stability, storage and controls – and, 
depending on the product classification, it may also include 
evidence from clinical performance studies; (4) device 
labelling, with instructions for use (including operating 
manual and user manual), patient information leaflet and 
promotional materials; (5) a summary of the risks identified 
and a description of how these risks have been controlled 
to an acceptable level; and (6) manufacturer information in 
order to identify manufacturing sites and to provide Quality 
Management System certification such as (ISO) 13485:2003 
and a description of the manufacturing process.15 A common 
dossier is to be piloted in Africa and other regions using a POC 
test as an example. Transparency of regulatory requirements 
and processes shall be promoted, preferably with documents 
available on line. Good Review Practice will include the 
monitoring and publication of the time required for review. 
Fees charged to companies should reflect the costs of the 
approval process and should not be seen as an opportunity 
for profit. Harmonisation of submission dossier requirements 
and adoption of a common template will: (1) reduce the cost 
to manufacturers of registering a product, a cost that would 
ultimately be passed to the consumers of the test; (2) reduce 
delays in test registration; (3) reduce barriers to marketing in 
small economies; and (4) facilitate harmonised approval of 
diagnostic devices, ultimately reducing the burden on NRAs 
and the cost of national regulatory approval. Harmonisation 
will require consensus on the fundamental principles of 
regulating diagnostic devices for health, but independent 
decision making shall be retained by the NRA. 
Convergence in the auditing of 
quality systems 
Regulatory oversight requires assurance that the 
manufacturer of the device conforms to a satisfactory quality 
management system. These quality management standards 
are universal and should not differ from country to country. 
The quality management system used by a manufacturer 
to control the quality of their product should be audited in 
order to provide assurance that safe and effective devices 
will be manufactured. The audit should make certain that 
specified minimum standards are met during manufacturing 
and provide impartial, reliable and objective evaluation of 
compliance with regulatory requirements. ISO 13485:2003 
is an international standard established for the manufacture 
of IVDs.17 If satisfactory quality management is not 
practised by the manufacturers, corrective measures may be 
recommended. For IVDs considered to have a risk of causing 
harm (to potential patients or users), assessment of adherence 
to satisfactory quality systems will include visiting the 
site of manufacture. Audit teams must encompass a range 
of skills and expertise enabling them to assess the quality 
management system and to determine the effectiveness of its 
implementation. The range of skills includes understanding 
the regulations and standards applicable to the specific IVD 
submitted for approval, the intended use and associated 
risks of the device, as well as the knowledge to assess the 
design, manufacturing processes and technologies involved. 
Convergence of quality standards and mutual or third-party 
recognition of inspection results could reduce duplication of 
efforts where teams representing different NRAs undertake 
independent audit of the same site, saving expenditure and 
reducing delays in regulatory approval.  
Status quo
Regulatory audits and site visits are costly for companies, 
with each audit costing as much as USD 200 000 (personal 
communication). Although costs are met in the first instance 
by the companies, they will ultimately be reflected in the 
price of the product and recouped from the end users. 
Duplication of audits inflates the cost of bringing a product to 
market and results in unnecessary delays. NRAs that require 
manufacturing site inspections for every medical device 
sold often have long delays in approving products for the 
market. In their 2012 annual report, the Brazilian National 
Health Surveillance Agency (ANVISA), reported a backlog 
of over 1000 products awaiting evaluation.18 NRAs in the 
developing world lack the expertise and capacity required 
in order to undertake audits, which ultimately results in 
delayed approval.  
Action going forward 
Minimum standards should be identified for quality 
management in the manufacture of POC diagnostics 
in addition to ISO 13485:2003.17 To reduce duplication, 
competent authorities or organisations capable of 
undertaking inspections should be identified and mutual 
recognition or recognition of competent third-party quality 
management audits adopted. In addition, mechanisms for 
sharing information should be established. 
Harmonisation of quality systems audits through 
convergence of standards and/or mutual recognition will 
make more efficient use of auditing resources and reduce 
the number of audits by different regulatory bodies for the 
same product, saving costs and reducing delays in new 
products reaching the market. Use of standardised audit 
protocols and expert bodies will streamline auditing, leading 
to improved quality management and product quality. This 
will provide greater consistency and increased confidence in 
audits. Enhanced consistency in audit practices and feedback 
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provided to manufacturers regarding quality management 
will facilitate improvements in manufacturing practice. The 
ultimate beneficiaries will be patients and users of diagnostic 
devices, who will gain an increased assurance that medical 
devices placed on the market are safe and effective whilst 
simultaneously ensuring that the costs of implementing an 
effective system do not unnecessarily inflate the price.  
Reducing duplication in studies of 
clinical performance
Pre-market approval of those IVDs considered to be high 
risk to individual or public health requires supporting 
evidence of the performance and operational characteristics 
of the device. For laboratory-based diagnostic tests, such 
evaluations are often conducted using well-characterised 
archived samples. If the new product is a POC test intended 
for use in decentralised health centres or dispensaries, 
evaluations of sensitivity, specificity, precision and ease of 
use should be conducted in the settings of intended use, with 
the test performed by the proposed end users.19 Such studies 
need to be based on sufficient sample size with assurance of 
quality so as to allow informed decisions on the performance 
and utility of the device as to whether the probable benefits 
of the device outweigh the risks. Data generated in clinical 
studies are presented to NRAs as part of the submission 
dossier for pre-market approval. The high cost of clinical 
trials and the length of time they require may result in higher 
cost of goods and significant delay in gaining access to new 
products that could potentially save lives.20
   
Status quo
The requirement of NRAs to have national trial data for 
approval has resulted in unnecessary duplication, where 
further studies provide little or no added scientific benefit.21,22 
High costs and delays incurred during clinical studies are a 
deterrent for companies entering the market, particularly in 
smaller countries where financial returns may be modest.9,12 
Costs borne by the manufacturer are ultimately passed on to 
the consumer, making devices less affordable. Since not every 
country has the capacity to conduct high quality studies in a 
timely manner, resulting from a lack of specialist facilities or 
limited access to appropriate patient groups, multi-country 
evaluations and NRAs coming together to review trial data 
and then making their own decisions for approval would be 
a more efficient approach. 
Action going forward
Multi-country studies using a standardised protocol and joint 
review of trial data should be encouraged in order to shorten 
trial duration and reduce duplication. A clinical trials registry 
should be established to reduce unintentional duplication 
and promote maximal use of resources. Clinical performance 
studies should be conducted by accredited laboratories and 
clinics with external oversight, so as to ensure conformity 
with international standards, including good laboratory 
and clinical practice.23,24,25 Prior joint approval of clinical 
and laboratory protocols by institutional review boards 
will ensure quality and acceptance by representatives of 
regulatory authorities.  
Reducing duplication of clinical trials will: (1) reduce the 
cost of accessing the market, making tests more affordable; 
(2) reduce delays in regulatory approval, accelerating access 
to new products; (3) reduce barriers to marketing in small 
economies; and (4) allow NRAs to maintain independent 
decision making for new products without requiring local 
trials.
Convergence in post-market 
surveillance 
Post-market surveillance ensures that products continue 
to meet expected safety and quality standards following 
approval by NRAs and an important component of 
regulatory oversight of diagnostic products for health.26 
Proactive post-market surveillance requires the systematic 
collection of data from laboratory studies in order to monitor 
test performance using a panel of appropriate reagents or, 
alternatively, through field testing using a panel of well-
characterised samples. Reactive surveillance requires 
manufacturers, or testers, to report problems voluntarily 
through an established reporting system. Such activities are 
applicable to manufacturers, importers and distributors. 
There is a need for cross-border, regional and global sharing 
of adverse events that threaten safety of individuals or 
public health so as to accelerate information gathering and 
enable substandard products to be withdrawn more quickly. 
The National Competent Authorities Report (NCAR) is a 
membership-based system open to those countries with 
stringent regulatory authorities.27 The system incorporates 
post-market surveillance, vigilance and reporting of adverse 
events and is aimed at improving safety by reducing the 
likelihood of repeated adverse events. There are two levels 
of NCAR participation. Full participation involves national 
competent authorities with established national adverse 
event reporting programmes. Being a full participant, a 
national authority receives both public and confidential or 
highly-sensitive information from other NCAR participants. 
Associate participants are a second tier of membership that 
receive public information, such as recall notices, safety and 
hazard alerts.  
Status quo
Currently, there is limited capacity for post-market 
surveillance in much of the developing world. Systems for 
post-market surveillance for diagnostic devices are not 
implemented globally26 and, in most developing countries, 
reporting and information sharing occurs on an ad hoc basis. 
In many countries, random quality checks, such as lot testing, 
are not performed and tests can enter the market without 
checks on their quality.21,28 Most developing countries lack 
a feedback mechanism to provide manufacturers with 
information regarding the need for corrective action as well 
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as a mechanism for removal of substandard tests that present 
a risk to public health. Disruption of services for some 
priority diseases, such as HIV, has occurred where publicity 
regarding quality problems has led, in some countries, to 
discontinuation of use without replacement devices being 
available.29 
Action going forward
A mix of proactive and reactive post-market surveillance 
activities should be encouraged. Reporting should be 
mandatory in the case of a death, a serious injury that is life 
threatening or results in permanent damage or impairment 
of a body function, or a malfunction. To implement post-
market surveillance for IVD medical devices in developing 
countries, regional networks of accredited laboratories 
should be established in order to undertake batch testing 
and monitor performance and safety. Standardised protocols 
should be established and reference quality assurance 
materials shared. These practices would promote good 
practice and instil confidence in the system, in addition to 
facilitating the exchange of data.  
Global and regional mechanisms should be established 
so as to facilitate investigation and procedural corrective 
actions or recalls for products found to be unsatisfactory. 
Harmonisation of proactive activities, such as batch 
monitoring, would enhance safety by reducing reporting 
delays, allowing prompt action to be taken should unsafe 
products be reported. Standardisation of protocols, test 
reagents and sample panels across geographic regions 
would assist surveillance whilst simultaneously minimising 
costs. National and transnational communication platforms 
are needed to simplify current procedures. Networks of 
accredited laboratories should be established to facilitate 
mutual recognition of surveillance data.   
Convergence of post-market surveillance activities will: 
(1) ensure that products continue to meet expected safety, 
performance and efficacy requirements following pre-
market approval; (2) prevent substandard tests, or batches of 
tests, from entering the market; (3) enable corrective actions 
to be taken by manufacturers; and (4) facilitate removal of 
substandard tests from the market, ultimately reducing costs 
and maximising efficient use of resources by NRAs. 
Conclusion
Diagnostic tests can play a vital role in improving access to 
effective healthcare, but the current regulatory landscape in 
developing countries creates significant barriers to market 
entry and has become a deterrent to innovation. Setting 
international standards and streamlining the regulatory 
process for in vitro diagnostic devices could diminish the 
regulatory burden. Four areas where action could lower 
costs, reduce delays, and accelerate access to quality 
diagnostic products for health are: (1) adoption of common 
registration requirements and submission dossier for pre-
market approval; (2) convergence of quality standards and 
mutual, or third-party, recognition of audit activities; (3) 
rationalisation of clinical performance studies in order to 
avoid unnecessary duplication; and (4) building transnational 
networks for post-market surveillance. 
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